Abomics, a pioneer in personalised medicine, buys Multirec

Finnish company Abomics Oy, a leading player in the field of pharmacogenetics in Europe, has acquired Multirec Oy, a healthcare information services company. Abomics specializes in pharmacogenetics and maintains a pharmacogenetics database, offering consulting services to clinical laboratories and healthcare professionals. Multirec is the leading provider of pharmaceutical databases for patient information systems in Finland. The two companies have collaborated for several years, distributing each other's databases.

The acquisition will make Abomics a comprehensive pharmaceutical information center. Abomics focuses on international markets and has already expanded its services to countries such as the Netherlands, Estonia, and Austria. The company's turnover is expected to exceed €3 million in 2023, and it aims to maintain its position in the growing field of pharmacogenetics.